ReviewNature reviews. Cardiology2026
Heart failure and obesity: novel insights leading to new treatment paradigms.
Review in Nature reviews. Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cardio-Kidney-Metabolic Phenotypes and Adverse Clinical Outcomes in Patients With Atrial Fibrillation.JACC. Asia · 2026Article
- Obesity in Heart Failure: Mechanistic, Diagnostic and Therapeutic Considerations.Cardiac failure review · 2026Review
- The cholesterol, high-density lipoprotein, and glucose index as a metabolic-nutritional biomarker for risk stratification in hospitalized heart failure patients.Frontiers in nutrition · 2026Article
- Relationship Between Right Ventricular Function and Body Composition in Adolescents and Young Adults.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) and obesity place a substantial burden on health-care systems worldwide. Obesity is associated with an estimated 5-7% increase in the incidence of new-onset HF for each unit increase in body mass index. This obesity-associated risk is more pronounced for HF with preserved ejection fraction than for HF with reduced ejection fraction. The relationship between HF and obesity has historically been underrecognized. However, because of the development of weight-loss drugs with beneficial effects on outcomes in patients with HF with preserved ejection fraction, this link is now clear. In this Review, we provide a summary of the effects of obesity on the development of HF, exploring the epidemiology and potential pathophysiological mechanisms linking these two conditions. We also discuss management strategies, including lifestyle interventions and novel pharmaceutical approaches. This Review adds an impetus to all practitioners of cardiovascular medicine, especially specialists in HF, to become well-versed in obesity management and underscores the need for further research on the effects of intentional weight loss in various cardiovascular conditions.
Indexed as
Identifiers
40721643What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.